Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelly Bui

Ophthalmology Seattle, WA Medical Doctor

NPI 1235367103 CMS profile 192589

1145 Broadway, Seattle, WA 98122

Open in the dashboard

General payments

$1,582

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Bui of Seattle, WA is reported in the CMS Open Payments database as having received $1,582 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $434 18
2024 General $344 13
2023 General $36 2
2022 General $297 5
2021 General $60 3
2020 General $42 2
2019 General $369 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Bui
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Kelly Bui were reported at $434. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Kelly Bui Ophthalmology median Middle half National median
2019 $369 $258 $104–$655 $163
2020 $42 $126 $45–$321 $114
2021 $60 $205 $76–$534 $132
2022 $297 $266 $100–$678 $149
2023 $36 $308 $117–$745 $160
2024 $344 $340 $127–$846 $164
2025 $434 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $263 10 payments
  2. Alimera Sciences, Inc. $213 2 payments
  3. Allergan Inc. $163 5 payments
  4. AbbVie, Inc. $157 7 payments
  5. Sun Pharmaceutical Industries Inc. $149 4 payments
  6. Regeneron Healthcare Solutions, Inc. $111 4 payments
  7. Genentech USA, Inc. $93 3 payments
  8. EyePoint Pharmaceuticals US, Inc. $82 4 payments
  9. Astellas Pharma US Inc $62 2 payments
  10. Tarsus Pharmaceuticals, Inc. $55 2 payments
  11. Other $233 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,535 52 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. ILUVIEN $194 1 payment
  2. Cequa $169 5 payments
  3. OZURDEX Retina $151 4 payments
  4. Clareon $116 5 payments
  5. VABYSMO $93 3 payments
  6. EYLEA $90 3 payments
  7. OZURDEX Eye Care $75 4 payments
  8. Izervay $62 2 payments
  9. EYLEA HD $57 2 payments
  10. XDEMVY $55 2 payments
  11. Other $543 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

715

Median for Ophthalmology: 891

Drug cost

$77,629

Median for Ophthalmology: $68,233

Branded share of claims

37.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 60 $43,069
Restasis Multidose Cyclosporine Brand 13 $8,093
Prednisolone Acetate Generic 145 $5,964
Prolensa Bromfenac Sodium Brand 14 $4,811
Bromfenac Sodium Generic 23 $3,983
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 65 $3,056
Difluprednate Generic 16 $2,181
Fluorometholone Generic 20 $1,493
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 81 $1,268
Latanoprost Generic 115 $931

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$362,806

Of which drugs: $168,044

Medicare patients

505

Average age 77

Services billed

3,522

283 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 43%
Ischemic heart disease 23%
Osteoporosis 23%
Diabetes 20%
Chronic kidney disease 19%
Cancer 15%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 19 184 $119,636
Injection, bevacizumab, 10 mg J9035 Office 18 51 $2,914

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OZURDEX
  • AbbVie, Inc. $45
$45 — —
Izervay
  • Astellas Pharma US Inc $30
$30 — —
VABYSMO
  • Genentech USA, Inc. $28
$28 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $21
$21 — —
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record